Interleukin-2-induced, melanoma-specific T cells recognize camel, an unexpected translation product of LAGE-1

International Journal of Cancer

Volumn 82, Issue 3, 1999, Pages 442-448

  Aarnoudse, Corlien A ^a   Van den Doel, Petra B ^a   Heemskerk, Bianca ^a   Schrier, Peter I ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPITOPE; GENE PRODUCT; INTERLEUKIN 2; MESSENGER RNA; PEPTIDE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ARTICLE; CANCER CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MONONUCLEAR CELL; OPEN READING FRAME; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; BASE SEQUENCE; CLONING, MOLECULAR; COS CELLS; DNA, COMPLEMENTARY; EPITOPE MAPPING; GENETIC CODE; HUMANS; INTERLEUKIN-2; MOLECULAR SEQUENCE DATA; PROTEIN BIOSYNTHESIS; SEQUENCE HOMOLOGY, NUCLEIC ACID; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033010380     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990730)82:3<442::AID-IJC19>3.0.CO;2-Z     Document Type: Article

References (25)

1. ABKEN, H., HOMBACH, A., REINHOLD, U. and FERINE, S., Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? Immunol. Today, 19, 2-5 (1998).
2. AOKI, T., TASHIRO, K., MIYATAKE, S., KINASHI, T., NAKANO, T., ODA, Y., KIKUCHI, H. and HONJO, T., Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. nat. Acad. Sci. (Wash.), 89, 3850-3854 (1992).
3. BOON, T. and VAN DER BRUGGEN, P., Human tumor antigens recognized by T lymphocytes. J. exp. Med., 183, 725-729 (1996).
4. CHN, Y.T., SCANLAN, M.J., SAHIN, U., TÜRECI, O., GURE, A.O., TSANG, S., WILLIAMSON, B., STOCKERT, E., PFREUNDSCHUH, M. and OLD, L.J., A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. nat. Acad. Sci. (Wash.), 94, 1914-1918 (1997).
5. D'AMARO, J., HOUBIERS, J.G., DRIJFHOUT, J.W., BRANDT, R.M., SCHIPPER, R., BAVINCK, J.N., MELIEF, C.J. and KAST, W.M., A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum. Immunol., 43, 13-18 (1995).
6. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D. and MULLIGAN, R., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. nat. Acad Sci. (Wash.), 90, 3539-3543 (1993).
7. DRIJFHOUT, J.W., BRANDT, R.M., D'AMARO, J., KAST, W.M. and MELIEF, C.J., Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. Hum. Immunol., 43, 1-12 (1995).
8. GANSBACHER, B., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R. and GILBOA, E., Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. exp. Med., 172, 1217-1224 (1990).
9. HÉRIN, M., LEMOINE, C., WEYNANTS, P., VESSIERE, F., VAN PEL, A., KNUTH, A., DEVOS, R. and BOON, T., Production of stable cytolytic T cell clones directed against autologous human melanoma. Int. J. Cancer, 39, 390-396 (1987).
10. JÄGER, E., CHEN, Y.T., DRIJFHOUT, J.W., KARBACH, J., RINGHOFFER, M., JÄGER, D., ARAND, M., WADA, H., NOGUCHI, Y., STOCKERT, E., OLD, L.J. and KNUTH, A., Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. exp. Med., 187, 265-270 (1998).
11. KAWAKAMI, Y., ELIYAHU, S., DELGADO, C.H., ROBBINS, P.F., RIVOLTINI, L., TOPALIAN, S.L., MIKI, T. and ROSENBERG, S.A., Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. nat. Acad. Sci. (Wash.), 91, 3515-3519 (1994).
12. KIM, T.S., DEKRUYFF, R.H., RUPPER, R., MAECKER, H.T., LEVY, S. and UMETSU, D.T., An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J. Immunol., 158, 4137-4144 (1997).
13. LETHÉ, B., LUCAS, S., MICHAUX, L., DE SMET, C., GODELAINE, D., SERRANO, A., DE PLAEN, E. and BOON, T., LAGE-1, a new gene with tumor specificity. Int. J. Cancer, 76, 903-908 (1998).
14. MAYRAND, S.-M. and GREEN, W.R., Non-traditionally derived CTL epitopes: exceptions that prove the rules? Immunol. Today, 19, 551-556 (1998).
15. OSANTO, S., BROUWENSTYN, N., VAESSEN, N., FIGDOR, C.G., MELIEF, C.J. and SCHRIER, P.I., Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. Hum. Gene Ther., 4, 323-330 (1993).
16. OSSENDORP, F., MENGEDE, E., CAMPS, M., FILIUS, R. and MELIEF, C.J., Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. exp. Med., 187, 693-702 (1998).
17. SCHOENBERGER, S.P., TOES, R.E., VAN DER VOORT, E.I., OFFRINGA, R. and MELIEF, C.J., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 393, 480-483 (1998).
18. TAHARA, H. and LOTZE, M.T., Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther., 2, 96-106 (1995).
19. TEPPER, R.I., PATTENGALE, P.K. and LEDER, P., Murine interleukin-4 displays potent anti-tumour activity in vivo. Cell, 57, 503-512 (1989).
20. VAN DEN EYNDE, B. and BRICHARD, V.G., New tumor antigens recognized by T cells. Curr. Opin. Immunol., 7, 674-681 (1995).
21. VAN ELSAS, A., AARNOUDSE, C., VAN DER MINNE, C.E., VAN DER SPEK, C.W., BROUWENSTIJN, N., OSANTO, S. and SCHRIER, P.I., Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine. J. Immunother., 20, 343-353 (1997).
22. VAN ELSAS, A., VAN DER MINNE, C.E., BORGHI, M., VAN DER SPEK, C.W., BRAAKMAN, E., OSANTO, S. and SCHRIER, P.I., CTL recognition of an IL-2 producing melanoma vaccine. In: M. Maio (ed.), Immunolgy of human melanoma. Tumor-host interaction and immunotherapy, pp.165-173, IOS, Amsterdam (1996).
23. VERSTEEG, R., NOORDERMEER, I.A., KRÜSE-WOLTERS, K.M., RUITER, D.J. and SCHRIER, P.I., c-Myc downregulates class I HLA expression in human melanomas. EMBO J., 7, 1023-1029 (1988).
24. WANG, R.F., JOHNSTON, S.L., ZENG, G., TOPALIAN, S.L., SCHWARTZENTRUBER, D.J. and ROSENBERG, S.A., A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol., 161, 3596-3606 (1998).
25. WANG, R.F., PARKHURST, M.R., KAWAKAMI, Y., ROBBINS, P.F. and ROSENBERG, S.A., Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. exp. Med., 183, 1131-1140 (1996).